Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry by Sjodin, S et al.
Sjödin et al. Clin Proteom  (2016) 13:4 
DOI 10.1186/s12014-016-9104-2
Targeting LAMP2 in human cerebrospinal fluid 
with a combination of immunopurification 
and high resolution parallel reaction monitoring 
mass spectrometry
Sjödin et al. 
Clinical Proteomics
Sjödin et al. Clin Proteom  (2016) 13:4 
DOI 10.1186/s12014-016-9104-2
RESEARCH
Targeting LAMP2 in human 
cerebrospinal fluid with a combination 
of immunopurification and high resolution 
parallel reaction monitoring mass spectrometry
Simon Sjödin1*, Annika Öhrfelt1, Gunnar Brinkmalm1, Henrik Zetterberg1,2, Kaj Blennow1 and Ann Brinkmalm1
Abstract 
Background: Alzheimer’s disease is the most common form of dementia. An increasing body of evidence suggests 
that endo-lysosomal dysfunction is a pathogenic mechanism of Alzheimer’s disease. Thus there is a potential for pro-
teins involved in the normal function of endo-lysosomal vesicles to act as biomarkers of disease. Herein we focused 
on the lysosomal protein LAMP2 that is involved in chaperone mediated autophagy.
Results: Using a combination of immunoprecipitation, digestion and nano-liquid chromatography tandem mass 
spectrometry we targeted and identified six tryptic LAMP2 peptides in human cerebrospinal fluid. Employing the 
identified proteotypic tryptic peptides a hybrid immunoprecipitation high resolution parallel reaction monitoring 
mass spectrometric method was developed for the relative quantitation of LAMP2. The method was evaluated in a 
number of experiments which defined the overall methodological as well as the analytical micro-liquid chromatog-
raphy mass spectrometric intra- and inter-day variability. We identified an overall methodological peptide depend-
ent intra-day variability of 8–16 %. The inter-day experiments showed similar results. The analytical contribution to 
the variation was minor with a coefficient of variation of 0.5–2.1 %, depending on the peptide. Using the developed 
method, with defined and limited variability, we report increased cerebrospinal fluid levels of three LAMP2 peptides in 
Alzheimer’s disease subjects (n = 14), as compared to non-Alzheimer’s disease controls (n = 14).
Conclusion: Altered LAMP2 levels in cerebrospinal fluid may indicate endo-lysosomal dysfunction in Alzheimer’s 
disease. However, further studies in larger cohorts comprised of well-defined patient materials are required. We here 
present a tool which can be used for exploring the relevance of the level of LAMP2 as a potential measure of lysoso-
mal dysfunction in Alzheimer’s disease or other neurodegenerative diseases.
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Background
Alzheimer’s disease (AD) is the most common form of 
dementia with a prevalence increasing with the increas-
ing age of the population [1]. At neuropathological 
investigation characteristic findings are extracellular 
plaques containing the amyloid β (Aβ) peptide [2] and 
intra-neuronal tangles consisting of the hyperphoshoryl-
ated and aggregated protein tau [3]. The identification of 
Aβ [4] instigated the development of a hypothesis stating 
that an imbalance in the production or clearance of the 
Aβ peptide is causative of the disease. This was coined 
the amyloid cascade hypothesis [5].
However, in a complex and heterogeneous disease 
such as AD that is characterized by protein aggregation, 
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a growing body of evidence indicates that there is also 
a dysfunction in the endo-lysosomal system [6]. In AD 
patients an increased lysosomal activity and biogen-
esis [7–9], as well as increased rate of endocytosis with 
enlarged endosomes [10–13] and an extensive accumula-
tion of autophagic vacuoles, especially in dystrophic neu-
rites [14, 15], has been found.
There are three types of autophagy; macro- and micro-
autophagy and chaperone mediated autophagy (CMA) 
[16]. CMA is a selective process occurring at the lysoso-
mal membrane where KFERQ or chemically equivalent 
amino acid motif carrying proteins are recruited by the 
cytosolic chaperone protein Heat shock cognate 71  kDa 
protein (hsc70) to the single pass lysosomal transmem-
brane protein, lysosome-associated membrane glyco-
protein 2 (LAMP2). The recruitment is followed by 
translocation and degradation of the target protein within 
the lysosomal lumen [17]. LAMP2 is considered to consti-
tute the rate limiting step in CMA [17]. Furthermore, the 
rate of autophagy decreases with ageing [18], which in the 
case of CMA is due to a decline in the amount of LAMP2 
[19]. This is thought to be a result of altered dynamics in 
the trafficking and recycling of LAMP2 from the lumen to 
the lysosomal membrane [20] and has potential implica-
tions in age related diseases such as AD.
A biomarker is a biomolecule that has molecular 
involvement in the pathological processes of the diseases 
it reflects [21]. There is an evident value of discovering 
and using biomarkers as these could aid clinical diagno-
sis, help in evaluating disease progress and risk or aid in 
monitoring treatment effects in clinical trials [22]. Cer-
ebrospinal fluid (CSF) is in close contact with the brain 
and is readily accessible through lumbar puncture. Thus 
CSF is considered an important source for detecting and 
measuring soluble biomarkers reflecting disease in the 
central nervous system [22]. The core CSF biomarkers 
for AD are the 42 amino acid long Aβ peptide (Aβ1–42), 
total tau protein (T-tau), and phosphorylated tau protein 
(P-tau) [23]. These are part of the diagnostic criteria for 
research purposes developed by the International Work-
ing Group for New Research Criteria for the Diagnosis 
of Alzheimer’s Disease [24]. Individually these perform 
with good specificity and sensitivity when discriminating 
patients with AD from controls [25, 26]. However, when 
discriminating between AD and other neurodegenerative 
or psychiatric disorders a combination of the biomark-
ers or using calculated ratios between them has to be 
employed [23, 26]. Furthermore, doing so also has been 
shown to result in a prediction of conversion from mild 
cognitive impairment to AD with high sensitivity and 
specificity [27].
There is a need to find biomarkers that are prognos-
tic, follow progression and increase our comprehension 
of complex neurodegenerative disorders. Given this and 
the pathological alterations known to occur in AD, where 
an increased lysosomal biogenesis [7–9] and an extensive 
accumulation of autophagic vacuoles [14, 15] are seen, 
proteins involved and associated with the endo-lysosomal 
system might serve as potential biomarkers reflecting this 
neuropathological feature of AD. Such a biomarker could 
hopefully add information to the established biomark-
ers and improve diagnostics and understanding of the 
disease. Recently, a number of endo-lysosomal proteins 
were identified at increased levels in CSF from patients 
with AD including LAMP2, Lysosome-associated mem-
brane glycoprotein 1 (LAMP1), Ras related protein Rab-3 
(Rab3), Ras related protein Rab-7 (Rab7), Early endosome 
antigen 1 (EEA1) and pro-Cathepsin L. This was accom-
plished using Western blotting [28].
Mass spectrometry (MS) is a powerful tool for identify-
ing proteins in biological materials and has the potential 
to reflect the full complexity and diversity of the pro-
teome. This renders it especially competent in biomarker 
discovery of proteins relevant in pathological conditions. 
Parallel reaction monitoring (PRM) is a MS method 
where all the fragment ions of a selected precursor ion 
are monitored simultaneously (i.e., in parallel) [29]. By 
the addition of corresponding isotope labeled peptides 
and the simultaneous recording of the labeled peptides’ 
fragment ions, quantitation can be accomplished. PRM 
has been enabled by the development of hybrid high res-
olution mass spectrometers such as the Q Exactive [30]. 
PRM offers highly selective and accurate measurements 
[29, 31] and in comparison to the alternative approach, 
selected reaction monitoring (SRM), PRM display similar 
linearity and dynamic range [29].
In this study we set out to develop a hybrid immuno-
precipitation high resolution PRM-MS (IP-HR-PRM-
MS) method that can be used for analyzing the level of 
LAMP2 in human CSF. With the developed method we 
report increased levels of LAMP2 peptides in CSF from 
individuals having an AD core biomarker profile com-
pared to subjects with a control biomarker profile. The 
developed method was evaluated in a number of experi-
ments which defined the intra- and inter-day sample 
variability of the method in its entirety as well as isolated 
to the analytical liquid chromatography (LC) tandem MS 
(MS/MS) detection of the analytes.
Results
Identification of LAMP2 in human CSF
The selective purification of LAMP2 with IP was con-
firmed both by Western blotting and LC–MS/MS analy-
sis (Fig. 1). With Western blotting LAMP2 was identified 
at approximately 80  kDa, Fig.  1a. Given the criteria for 
identification (see “Bioinformatic analysis” in “Methods” 
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section), LAMP2 was identified in human CSF using IP, 
digestion with trypsin and analysis of tryptic peptides 
with nano-LC–MS/MS (Additional file 1: Table S1). The 
number of identified tryptic peptides was six when dis-
solving the precipitated samples with NH4HCO3 and 
four when using RapiGest SF (Additional file 2: Table S2). 
Subsequently NH4HCO3 was used to dissolve immuno-
precipitated LAMP2. The best scoring peptides are pre-
sented in Table 1 and their positions along the sequence 
of LAMP2 are shown in Fig. 1b. As seen in the figure the 
peptides identified span over a large sequence range of 
LAMP2 (74  % sequence length coverage). Correspond-
ing fragment ion spectra for the six identified peptides 
are shown in Additional file  3: Figure S1–S6. Both the 
Western blotting and LC–MS/MS analysis indicate that 
LAMP2 was selectively immunoprecipitated as no iden-
tification was made in negative controls, precipitated 
with an unselective antibody, by either technique. Inter-
estingly, hsc70 (UniProtKB:P11142-2 and E9PI65) was 
co-immunoprecipitated and identified together with 
LAMP2 (Additional file 1: Table S1). 
Quantitation of LAMP2 in human CSF using IP‑HR‑PRM‑MS
We designed a strategy for relative quantitation of 
LAMP2 in CSF by combining selective purification with 
IP, addition of stable isotope labeled standards, digestion 
with trypsin, and MS-based quantitation. The MS-based 
quantitation was performed by separation of the peptides 
on a Dionex UltiMate 3000 micro-LC combined with 
HR-PRM-MS. Initially, the performance of four selected 
isotope labeled peptides in the LC-HR-PRM-MS method 
was evaluated by the injection of three peptide mixtures 
from ten individual LC vials or ten times from a single 
vial. For each injection the sum of areas of selected frag-
ment ions (Table 1) was normalized against the average 
sum of area for the group of sample replicates. Thus, the 
relative deviation for each injection from the group was 
calculated. There was no apparent difference in variation 
Fig. 1 Validation of immunoprecipitation and identified LAMP2 peptides in CSF. a By employing Western blotting LAMP2 was detected when CSF 
had been immunoprecipitated with an anti-LAMP2 selective antibody, lane 1, and was found to migrate at approximately 80 kDa. LAMP2 was not 
precipitated using mouse serum IgG antibodies, lane 2. The detection was neither a result of unspecific binding of the secondary antibody as seen 
in the right panel. MW molecular weight ladder. b Shown is the sequence and theoretical structure of LAMP2A (UniProtKB:P13473) as indicated; 
signal peptide, aa 1–28; hinge region, aa 193–228; transmembrane region, aa 376–399; cytoplasmic tail, aa 400–410. Furthermore, the positions of 
the tryptic LAMP2 peptides identified by nano-LC–MS/MS are indicated
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between injections from multiple LC vials or multiple 
times from a single vial or between the three peptide 
mixtures (Additional file  3: Figure S7). The coefficient 
of variation (CV) from injection to injection was found 
to vary for the LAMP2 peptides (aa 133–144, 145–152, 
153–161 and 334–351) in the ranges of 3–19, 1–6, 2–8 
and 24–70 %, respectively for the three peptide mixtures. 
For the isotope labeled bovine serum albumin (BSA) pep-
tide aa 421–433 the CV was found to vary between 8 and 
31 % (Additional file 3: Figure S8).
By using two methodological workflows, the intra- and 
inter-day variability of the IP-HR-PRM-MS method and 
the analytical LC-HR-PRM-MS intra- and inter-day vari-
ability were evaluated (Fig. 2). The results of this evalua-
tion are shown for the LAMP2 peptides in Fig. 3 and for 
the BSA aa 421–433 peptide in Additional file 3: Figure 
S9. Selected fragment ions for each peptide (Table  1) 
were used to calculate a ratio between the sum of frag-
ment ion areas of the tryptic peptide against the sum of 
areas of the added isotope labeled peptide. The calculated 
ratio was used in the evaluation. The overall method vari-
ability was determined by Workflow 1 for the LAMP2 
peptides (aa 133–144, 145–152, 153–161 and 334–351). 
The intra-day variability for the peptides was found to 
vary in the ranges of 11–16, 8–15, 10–13 and 39–50 %, 
respectively, for samples prepared on three different 
occasions. The corresponding inter-day CVs were 17, 10, 
15 and 42 %, respectively. The intra-day CVs for the BSA 
peptide aa 421–433 varied between 8 and 15 % and the 
inter-day CV was 11 %. The analytical LC-HR-PRM-MS 
analysis variability was determined by Workflow 2 for 
the LAMP2 peptides (aa 133–144, 145–152, 153–161 
and 334–351). Here the intra-day variability varied in the 
ranges of 0.8–1.1, 0.5–0.7, 1.5–2.1 and 35–43  % for the 
four peptides, respectively, between the three samples 
sets prepared on different occasions (Batch 1–3). The 
corresponding inter-day CVs were 11, 6, 12 and 44  %, 
respectively. The LAMP2 peptide aa 334–351 was sub-
sequently excluded from the method due to the demon-
strated high variability. The intra-day CVs varied between 
1.1 and 1.7  % for the BSA peptide aa 421–433 and the 
inter-day CV was 5.6 %. Examples of HR-PRM total ion 
current chromatograms and corresponding ion fragment 
mass spectra are shown for the LAMP2 peptides aa 133–
144, 145–152, 153–161, 334–351 and BSA aa 421–433 
in Additional file 3: Figures S10–S14, respectively. Since 
the variation in the LC–MS method alone was limited, 
as determined by the above evaluation, we decided to 
perform a single LC-HR-PRM-MS measurement of each 
sample in the study below. 
Measuring the level of LAMP2 in CSF in subjects with an 
AD core biomarker profile
When employing the developed IP-HR-PRM-MS 
method, the levels of the three investigated tryptic 
LAMP2 peptides were found to be increased in subjects 
with an AD core biomarker profile (see “CSF samples” in 
“Methods” section) compared with subjects with a con-
trol biomarker profile. These increases were significant 
for LAMP2 aa 133–144 and 145–152 (p = 0.024, 95 % CI 
0.043–0.81 and p =  0.039, 95  % CI 0.015–0.75, respec-
tively) but not for aa 153–161 (p = 0.10, 95 % CI −0.094 
to 1.12) (Fig. 4). Furthermore, a set of ten quality control 
(QC) CSF pool sample replicates analyzed in randomized 
integrated succession with the subject samples showed 
a variation in CV between 10 and 22 % for the LAMP2 
peptides (aa 133–144, 145–152 and 153–161) and for the 
BSA aa 421–433 peptide (Additional file 3: Figure S15). In 
addition the levels of the three peptides measured in each 
individual in the AD group were found to be highly cor-
related as calculated using Spearman’s test of correlation 
with a Spearman’s ρ of 0.86, 0.87 and 0.93 for the peptide 
Table 1 Identified LAMP2 peptides by employing hybrid immunoprecipitation nano-LC–MS/MS
The table shows the LAMP2 peptides identified in human CSF by nano-LC–MS/MS. The identification statistics values are shown for the peptides identified with 
highest confidence
a Cysteine’s were subjected to carbamidomethylation through alkylation
b The name of the peptides are given according to their amino acid (aa) sequence position
c Fragment ions used for quantitation and evaluating the HR-PRM-MS method as well as the fragment ions of the added BSA peptide
Sequencea Peptideb Mascot ion score Mascot expect Fragment ionsc
WQMNFTVR LAMP2 aa 46–53 36 4.8 × 10−3 –
GILTVDELLAIR LAMP2 aa 133–144 81 6.9 × 10−8 y5, y6, y7, y8, y9
IPLNDLFR LAMP2 aa 145–152 50 2.2 × 10−4 y4, y5, y6, y7
CNSLSTLEK LAMP2 aa 153–161 59 2.7 × 10−5 y4, y5, y6, y7
YLDFVFAVK LAMP2 aa 281–289 33 1.5 × 10−2 –
EQTVSVSGAFQINTFDLR LAMP2 aa 334–351 101 1.7 × 10−9 y6, y7, y8, y9, y10, y11, y12, y13, y14
LGEYGFQNALIVR BSA aa 421–433 – – y4, y6, y7, y8, y9, y10
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combinations aa 133–144/145–152, 133–144/145–152 
and 145–152/153–161, respectively (Additional file  3: 
Figure S16A–C). The corresponding Spearman’s ρ in 
the control group were 0.84, 0.86 and 0.89, respectively 
(Additional file 3: Figure S16D–F). The slopes of all cor-
relations were significantly different from 0 (p  <  0.01). 
However, there was no apparent correlation between the 
LAMP2 peptides and the CSF core biomarkers, Aβ1–42, 
Fig. 2 Strategy for evaluating hybrid immunoprecipitation HR-PRM-MS method variability. The variability in the IP-HR-PRM-MS method targeting 
selected LAMP2 peptides was evaluated by employing two methodological pathways, Workflow 1 and Workflow 2. Workflow 1 targeted the overall 
variability of the method whereas Workflow 2 was designed to isolate the variability in the LC-HR-PRM-MS analysis. Using a single QC pool of human 
CSF LAMP2 was immunoprecipitated on three separate occasions, Batch 1–3, which contained 8 + 8 replicate samples each (eight for each work-
flow). This enabled determination of intra- and inter-day variation. After the immunoprecipitation, isotope labeled LAMP2 peptides corresponding 
to the peptides previously identified using nano-LC tandem MS were added as well as full length BSA and an isotope labeled BSA peptide. The 
samples were then digested by trypsin. In Workflow 1 each sample was processed individually from beginning to end, thus reflecting the overall 
methodological variability. In Workflow 2 the eight replicate samples in each batch were pooled after trypsination. Thus, Workflow 2 was equivalent 
to eight injections of the same sample, for the respective batch, in the micro-LC HR-PRM-MS analysis. Although the different batches were prepared 
on different occasions they were all analyzed on a single occasion to minimize the influence of altering instrumental performance
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Fig. 3 Hybrid immunoprecipitation HR-PRM-MS method variability. Using two methodological workflows (Fig. 2) the variability in the IP-HR-PRM-
MS method targeting LAMP2 peptides was evaluated. Workflow 1 reflects the overall variability of the method whereas Workflow 2 isolated the 
variation in the micro-LC HR-PRM-MS analysis. Workflow 1 and 2 each included samples prepared on three separate occasions, Batch 1–3, each 
including 8 + 8 technical replicates. The different batches were analyzed on a single occasion to minimize the influence of altering instrumen-
tal performance. The workflow enabled determination of intra- and inter-day coefficients of variations (CVs), where the intraday variation was 
calculated for each batch and the inter-day variation calculated for the samples included in all three batches. The intra- and inter-day CVs for the 
workflows are shown for the LAMP2 peptides; a aa 133–144, b aa 145–152, c aa 153–161; and d aa 334–351. The bar graphs show the calculated 
ratio between the sum of the included fragment ion peak areas of the tryptic peptide against the sum of peak areas of the added isotope labeled 
peptide for each sample and within each batch sorted, from left to right, in order of analysis
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T- and P-tau with threonine phosphorylation at position 
181 (P-tau181), neither in the AD core biomarker profile 
group (Additional file  3: Figure S17) nor in the control 
group (Additional file 3: Figure S18).
Discussion
We identified several LAMP2 peptides in human CSF 
using a combination of IP, trypsination and MS. Employ-
ing the identified peptides we have developed an IP-HR-
PRM-MS method that can be used to measure levels of 
LAMP2 in clinically relevant amounts of CSF. Using the 
developed method we identified higher CSF concentra-
tions of LAMP2 tryptic peptides in subjects with an AD 
core biomarker profile as compared to control subjects.
The six identified LAMP2 peptides have a sequence 
length coverage of 74 % suggesting that a larger fragment 
of LAMP2 does exist in CSF. LAMP2 is produced in three 
spliced forms A, B and C (UniProtKB:P13473, P13473-2 
and P13473-3, respectively), in which the isoform speci-
ficity is contained within the C-terminal end which 
remained undetected in these experiments. LAMP2 was 
also identified after IP using Western blotting. LAMP2 
is a 45  kDa highly glycosylated protein which might 
explain why we detect it at 80 kDa. However, the peptides 
we have identified and used herein do not contain any 
known glycosylation sites. Furthermore, the ratios calcu-
lated for the three LAMP2 peptides aa 133–144, 145–152 
and 153–161 showed a good correlation suggesting that 
they are a measure of the same entity and that they are 
produced with similar efficiency by tryptic degradation.
Next, we developed an IP-HR-PRM-MS method for 
quantitation of LAMP2 in CSF and determined the vari-
ation of the method. First the performance of the isotope 
labeled peptides in the method was investigated. Sec-
ond, utilizing two methodological workflows the over-
all method variability and the isolated LC-HR-PRM-MS 
performance was defined. The latter was found to have 
a low contribution to the overall methodological varia-
tion. The overall methodological variation was found to 
be peptide dependent and to have CVs in the range of 
8–16 %. We found a limited effect of preparing the sam-
ples on different days as concluded by comparing intra- 
with inter-day CVs. The variation identified herein using 
the two methodological workflows identified the non-
biological contribution as all samples were prepared from 
a single QC CSF pool. Piehowski et al. [32] isolated the 
variance in different experimental parts when perform-
ing quantitative proteomics on brain tissue and found 
the main contributor to be dissection and homogeniza-
tion (72  %) while instrumental variance only accounted 
for 16  %. Similarly, Addona et  al. [33] identified sample 
preparation to be the main contributor to SRM method 
variation. In an IP-HR-PRM-MS method the sample 
preparation can be controlled for by an early addition of 
an internal isotope labeled standard. However, if using 
IP this requires that the standard carries a functional 
epitope and a sequence or conformation which does 
not impact the proteolytic processing as compared with 
its endogenous equivalent. Here, BSA was added as an 
external control of method stability to monitor the effi-
ciency of the tryptic degradation in-between samples. 
Furthermore, since the same amount of BSA protein and 
its labeled standard was added to all samples, the LC–
MS/MS stability could be monitored.
Although initially considered for inclusion in the 
analysis, the low repeatability of the LAMP2 peptide aa 
334–351 led to its exclusion. This highlights the impor-
tance of a thorough analysis of the proteotypic peptides 
chosen for analysis in quantitative methods such as PRM 
and encourages the initial inclusion of several peptides 
to ensure methodological robustness and successful 
method development. Different peptides perform differ-
ently in PRM and other LC–MS based methods, which 
was indicated by the difference in variance between the 
peptides used in this work. This was also shown by the 
multicenter study performed by Addona et  al. [33]. In 
the method described in this report the sum of areas of 
4–5 fragment ions, depending on peptide, was used. The 
Fig. 4 Scatterplots comparing LAMP2 peptide levels between AD 
and control subjects. Employing the IP-HR-PRM-MS method the level 
of three LAMP2 peptides were compared between a set of control 
(n = 14) and Alzheimer’s disease (AD; n = 14) subjects. a Significant 
higher level of the peptides a LAMP2 aa 133–144 (p = 0.024, 95 % 
CI 0.043–0.81) and b aa 145–152 (p = 0.039, 95 % CI 0.015–0.75) 
was found in the AD compared to the control group. This was not 
significant for the c aa 153–161 peptide (p = 0.10, 95 % CI −0.094 to 
1.12). Shown is the calculated ratio between the sum of the included 
fragment ion peak areas of the tryptic peptide against the sum of 
peak areas of the added isotope labeled peptide for each individual 
subject. For each group the median and interquartile range are indi-
cated. Groups were compared using Mann–Whitney’s U test of ranks
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fragment ions used were selected based on having a high 
intensity, being reproducibly detected and having no 
background interference. These aspects were confirmed 
by manual inspection and with the assistance of an in-
house developed software. A higher number of utilized 
fragment ions should in general improve the robustness 
of the method, limit the influence of interfering contami-
nants [33] and possible inclusion of false positive PRM 
peaks [34]. However, in our report individual fragment 
ion peak areas performed equally well as sum of areas 
in regard to sample variation (data not shown). Further-
more, with increasing instrumental resolution the risk for 
influence of contaminants decreases. In this report a MS 
and MS/MS resolution setting of 70,000, at 200 m/z, was 
used. Recently we have developed a similar PRM method 
targeting synaptic pathology by measuring the relative 
amount of the SNARE complex protein synaptosomal-
associated protein 25 (SNAP-25) in human CSF and 
brain tissue [35, 36]. This highlights the potential of PRM 
methods in neurobiological biomarker discovery and 
development.
In a comparison between CSF from subjects with an 
AD core biomarker profile with subjects with a control 
biomarker profile (n = 14 + 14) we found a significantly 
increased level of LAMP2 tryptic peptides in the individ-
uals with an AD core biomarker profile. Our findings are 
in agreement with Armstrong et al. [28] who also inden-
tified increased levels of LAMP2 and a number of other 
endo-lysosomal proteins in a similar material of individu-
als. However, Armstrong et  al. [28] reported a correla-
tion between the level of LAMP2 with P-tau181, which we 
failed to replicate, potentially due to the lower number of 
individuals examined in our study.
An increase in the level of LAMP2 in CSF could be 
explained by the increased lysosomal biogenesis that 
occurs in neurons in AD [7–9]. In a PS1/APP mouse 
model Torres et  al. [37] described an increased level of 
LAMP2 and LAMP1 in the hippocampus. The increases 
were associated with plaques in this region. Contrasting 
this, the level of LAMP2 has been suggested to decline 
with ageing [19]. However, both LAMP2 and hsc70 have 
been shown to exist at decreased levels in the substantia 
nigra and amygdala in subjects with Parkinson’s disease 
by Alvarez-Erviti et al. [38], whereas no alterations were 
found for LAMP2 and hsc70 in AD subjects in these two 
regions. We found that hsc70 was co-immunoprecipi-
tated with LAMP2 which is interesting considering the 
functional interaction between these proteins in which 
hsc70 is responsible for the recruitment of CMA sub-
strate KFERQ motif carrying proteins to LAMP2 [39]. 
The specificity of potential CSF candidate biomarkers 
from the endo-lysosomal system should be thoroughly 
investigated because of the reported involvement in 
several neurodegenerative diseases, such as Parkinson’s 
disease, Huntington’s disease, amyotrophic lateral scle-
rosis, frontotemporal dementia, etc., as described and 
reviewed elsewhere [16, 40, 41]. Also CMA, specifi-
cally, has been implicated in the degradation of proteins 
associated with a number of neurodegenerative diseases 
as exemplified in tauophaties [42], Parkinson’s disease 
[43–46] and Huntington’s disease [47, 48]. Furthermore, 
the conclusions drawn from our findings in relation to 
AD should be made with consideration as the individuals 
included herein are not clinically diagnosed.
Conclusion
We have identified LAMP2 in human CSF using a com-
bination of IP and MS. An IP-HR-PRM-MS method 
has been developed which can be used for comparing 
LAMP2 concentrations in clinically relevant amounts 
of human CSF. With the developed method which has a 
defined and limited methodological variability, we have 
measured significantly higher levels of LAMP2 peptides 
in a group of subjects with an AD core biomarker pro-
file compared with a group with a control biomarker pro-
file. Identifying new potential biomarkers might aid us in 
understanding complex neurodegenerative diseases. Fur-
ther explorations in prospective studies, larger cohorts 
and/or of biomarker disease specificity are required to 
determine the relevance of the level of LAMP2 as a meas-
ure reflecting the neuropathology of AD or other neu-
rodegenerative diseases. Herein we present a tool which 
can be used for aiding such an endeavor.
Methods
CSF samples
CSF samples were supplied by the clinical routine at the 
Clinical Neurochemistry Laboratory, The Sahlgrenska 
University Hospital, Mölndal, Sweden. The CSF samples 
were decoded. Subjects were designated as AD accord-
ing to CSF AD core biomarker cut-off levels of; T-tau 
>400 ng/L, P-tau181 >80 ng/L and Aβ1–42 <600 ng/L. The 
test material included 14 subjects with an AD core bio-
marker profile and 14 subjects with a control biomarker 
profile for which the demographics are presented in 
Table 2. The QC CSF pool sample used for method devel-
opment had a T-tau level of 167 ng/L, P-tau181 of 68 ng/L 
and Aβ1–42 of 400 ng/L. The study was approved by the 
ethics committee at the University of Gothenburg.
Analysis of CSF AD core biomarkers
The CSF analyses on Aβ1–42, T-tau and P-tau181 levels 
were performed using commercially available ELISA 
assays from Fujirebio [INNOTEST β-AMYLOID(1–42), 
INNOTEST hTau Ag and INNOTEST PHOSPHO-
TAU(181P); Fujirebio Europe, Ghent, Belgium].
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Immunoprecipitation
IP from CSF was performed as described previously 
with minor modifications [35]. In short, 50 µL magnetic 
beads conjugated to anti-mouse IgG antibodies (Dyna-
beads M280, Invitrogen, Thermo Fisher Scientific Inc., 
Waltham, MA, USA), pre-washed in phosphate buff-
ered saline (PBS) were incubated on rocking platform 
with 2 µg anti-LAMP2 mouse monoclonal (Abcam plc., 
Cambridge, UK) or mouse serum IgG antibodies (Sigma-
Aldrich Co., St. Louis, MO, USA) for 1  h at room tem-
perature. After a subsequent wash with PBS the beads 
were incubated on a rocking platform with Rotiblock 
(Carl Roth GmbH, Karlsruhe, Germany) diluted 1:10 in 
PBS for 1  h at room temperature. The magnetic bead–
antibody complex was then washed and diluted in PBS to 
the original volume. The beads were added to 445 µL CSF 
(approximately 130 µg protein) and incubated with a final 
concentration of 0.2 % Triton X-100 over night at +8 °C. 
Using a KingFisher mL Magnetic Particle Processors sys-
tem (Thermo Fisher Scientific Inc.) the beads were subse-
quently washed in 0.025 % Tween in PBS, PBS and finally 
50  mM NH4HCO3 before being eluted in 0.5  % formic 
acid. The eluate was dried by vacuum centrifugation.
Western blotting
Precipitated samples were dissolved in 1  ×  NuPAGE 
LDS sample buffer (NuPAGE, Thermo Fisher Scientific 
Inc.) and separated on a 4–12 % tris–glycine gel (Novex, 
Thermo Fisher Scientific Inc.). Proteins were transferred 
to a PVDF membrane (Immobilion-P, Merck KGaA, 
Darmstadt, Germany) which was subsequently blocked 
in 5 % non-fat milk in PBS with 0.05 % Tween (PBS-T). 
Membranes were incubated with a primary polyclonal 
rabbit anti-LAMP2 antibody (Santa Cruz Biotechnology, 
Inc., Dallas, TX, USA), diluted 1:1000 in 5 % non-fat milk 
in PBS-T, overnight at +8 °C. Negative controls of West-
ern blotting were incubated without a primary antibody 
in 5 % non-fat milk in PBS-T. Membranes were washed 
in PBS-T and then incubated with a secondary anti-rab-
bit IgG antibody conjugated with biotin (Sigma-Aldrich 
Co.) diluted 1:10,000 in PBS-T, at room temperature 
for 1  h. After a subsequent wash in PBS-T, membranes 
were incubated with a streptavidin conjugated Horse-
radish Peroxidase (Amersham, GE Healthcare UK Ltd., 
Little Chalfont, UK) diluted 1:3000 in PBS-T, for 1  h at 
room temperature. After a final wash in PBS-T, detec-
tion of proteins were made by exposing membranes to 
ECL select (Amersham, GE Healthcare UK Ltd.) and by 
recording the chemiluminescence signal using a Fuji-
film LAS-3000 camera (Fuji Photo Film Co., Ltd., Tokyo, 
Japan) and the Image Reader LAS-3000 v2.2 software 
(Fuji Photo Film Co., Ltd.). The images were finally pro-
cessed by Multi Gauge v3.0 (Fuji Photo Film Co., Ltd.).
Protein digestion for protein and peptide identification
Immunoprecipitated samples, eluted and dried, were 
dissolved by agitation at room temperature for 1 h after 
the addition of either 10  µL of 50  mM NH4HCO3 or 
0.1  % RapiGest SF (Waters Co., Milford, MA, USA) in 
50 mM NH4HCO3 for a qualitative comparison of recov-
ery. 10  µL 10  mM dithiothreitol (Sigma-Aldrich Co.) in 
50 mM NH4HCO3 was added to the samples which were 
then reduced by incubation at +90  °C for 3  min. After 
cooling to room temperature, 5  µL of 10  mM iodoacet-
amide (Sigma-Aldrich Co.) in 50  mM NH4HCO3 was 
added to the samples which were alkylated in the dark 
at room temperature for 30  min. Then, 5 µL of 5  mg/L 
sequencing grade modified trypsin (Promega Co., Madi-
son, WI, USA) in 50 mM NH4HCO3 was added and the 
samples were incubated at +37  °C overnight (approxi-
mately 18  h). Incubation was ended by the addition of 
2  µL 10  % trifluoroacetic acid after which the samples 
dissolved in 0.1  % RapiGest SF, were further incubated 
for 45 min at +37 °C. This was followed by centrifugation 
at +4 °C, 16,910g for 10 min and the resulting superna-
tant was transferred to 300-µL-LC vials (Sun-Sri, Thermo 
Fisher Scientific Inc.).
Nano‑liquid chromatography MS/MS analysis
Digested triplicate samples and corresponding immu-
noprecipitated negative controls were separated using a 
Dionex UltiMate 3000 nano-LC system (Thermo Fisher 
Scientific Inc.) with an Acclaim PepMap 100 nanoViper 
C18 trap column (length 20 mm; inner diameter 75 µm; 
particle size 3 µm; Thermo Fisher Scientific Inc.) and an 
Acclaim PepMap RSLC nanoViper C18 column (length 
500  mm; inner diameter 75  µm; particle size 2  µm; 
Thermo Fisher Scientific Inc.). Mobile phases were; 
A: 0.1  % formic acid in water (v/v) and B: 0.1  % formic 
acid and 84 % acetonitrile in water (v/v). Separation was 
Table 2 Demographics of  control and  Alzheimer’s disease 
subjects
Control and Alzheimer’s disease (AD) subjects were chosen and included in the 
study based on having an AD or control core biomarker profile. Mann–Whitney 
U test of ranks were used for evaluating statistical significant differences, 
determined as calculated p values of <0.05. Values are presented as median 
(interquartile range)
Control AD Statistics  
(Mann–Whitney)
N 14 14 –
Age 70.5 (12.5) 76 (11.75) >0.05
Female (%) 43 % 50 % >0.05
T-tau (ng/L) 232 (97) 1035 (321.25) <0.001
P-tau181 (ng/L) 38 (8.5) 91 (11.5) <0.001
Aβ1–42 (ng/L) 985 (323) 450 (209.25) <0.001
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performed at a flow rate of 150  nL/min, at +40  °C on 
a gradient going from 5 to 40  % B over 50  min directly 
followed by an increase from 40 to 80 % B over 10 min. 
LC–MS/MS were acquired by a LC online connection 
to a hybrid quadrupole–orbitrap mass spectrometer, Q 
Exactive (Thermo Fisher Scientific Inc.) operating in pos-
itive ion mode with a dynamic nano-spray probe (NSI), 
a spray voltage of 1.7 kV and capillary transfer tube tem-
perature of +275  °C. Full mass spectra (350–1400 m/z) 
were acquired at a resolution setting of 70,000 (at m/z 
200), an AGC target of 1 ×  106 and a maximum injec-
tion time of 250 ms. This was followed by higher-energy 
collisional dissociation (HCD) production of fragment 
ions and recording of MS/MS at a resolution setting of 
17,500, an AGC target of 5 × 104 and a maximum injec-
tion time of 60  ms. Single micro-scans were collected 
with an isolation width of 2 m/z using an inclusion list of 
doubly and triply charged proteotypic tryptic LAMP2A, 
B and C peptides (UniProtKB:P13473, P13473-2 and 
P13473-3, respectively). When idle, data dependent top 
10 MS/MS scans were collected by utilizing an intensity 
threshold of 1.7  ×  104, exclusion of unassigned, singly, 
and >5 +  charged ions, a dynamic exclusion of 5  s and 
loop count of 10.
Bioinformatic analysis
Database searches were performed using Thermo Pro-
teome Discoverer v1.4 (Thermo Fisher Scientific Inc.) 
and an in-house Mascot database server v2.3.2 (Matrix 
Science Ltd., London, UK). Peak lists were generated 
using default settings. The search parameters were: data-
base (UniProtKB_Human 131030, 88,266 sequences and 
35,040,462 residues), taxonomy (all entries), enzyme 
(trypsin), maximum missed cleavages (1), variable mod-
ification (methionine oxidation), fixed modification 
(cysteine carbamidomethylation), instrument type/
fragmentation type (1+ and 2+ charged b- and y-ions), 
peptide mass tolerance (10 ppm) and fragment mass tol-
erance (20 mmu). Positive protein identification was con-
sidered those proteins identified with at least two unique 
peptides, identified in a minimum of two replicate sam-
ples and absent in negative controls immunoprecipitated 
with mouse serum IgG antibodies. Positive peptide iden-
tification was considered peptides identified in a mini-
mum of two samples, both of which received a Mascot 
ion score of ≥30 and a Mascot expect value of <0.05.
Protein digestion and addition of heavy‑isotope labeled 
peptide standards for quantitation
Immunoprecipitated dried samples were dissolved in 10 
µL 50 mM NH4HCO3 containing 16 nM of the LAMP2 
isotope labeled peptides aa 133–144 GILTVDELLAI[R] 
([R]  =  13C/15N labeled R), 145–152 IPLNDLF[R], 
153–161 C[cam]NSLSTLE[K] ([cam]  =  cysteine carba-
midomethylation; [K] =  13C/15N labeled K), 166  nM of 
the peptide aa 334–351 EQTVSVSGAFQINTFDL[R] 
and 23  nM of the BSA peptide aa 421–433 
LGEYGFQNALIV[R] (HeavyPeptide FasTrack 1 crude 
peptides, >95  % peptide purity and >99  % isotopic 
enrichment, Thermo Fisher Scientific Inc.) as well as 
23 nM of full length BSA protein [(UniProtKB:P02769); 
≥98  % purity, Sigma-Aldrich Co.]. Samples were dis-
solved by agitation at room temperature for 1  h and 
then reduced, alkylated and digested with trypsin as 
described above. Trypsination was ended by the addition 
of 5  µL 10  % formic acid followed by centrifugation of 
the samples at +4 °C, 16,910g for 10 min after which the 
supernatant was transferred to 300-µL-LC vials (Sun-Sri, 
Thermo Fisher Scientific Inc.).
LC‑HR‑PRM‑MS
LC-HR-PRM-MS analyses were performed on an online 
LC–MS system consisting of a Dionex UltiMate 3000 
standard-LC system (Thermo Fisher Scientific Inc.) cou-
pled to a quadrupole-orbitrap mass spectrometer, Q 
Exactive (Thermo Fisher Scientific Inc.). 15 µL of injected 
samples were separated over a Hypersil GOLD HPLC 
C18 column (length 100  mm; inner diameter 2.1  mm; 
particle size 1.9  µm; Thermo Fisher Scientific Inc.) at a 
flow rate of 100 µL/min at +40 °C. Mobile phases were; 
A: 0.1  % formic acid in water (v/v) and B: 0.1  % formic 
acid and 84 % acetonitrile in water (v/v). A linear increase 
from 20 to 50 % B over 20 min was used for separation. 
HR-PRM MS and MS/MS acquisitions were performed 
with the Q Exactive operating at positive mode with a 
scheduled inclusion list targeting the doubly charged 
LAMP2 peptides aa 133–144, 145–152, 153–161, 334–
351 and the BSA peptide aa 421–433 with an isolation 
window of 8 m/z, thus including each tryptic and isotope 
labeled peptide pair in a single scan. Single micro-scan 
MS and MS/MS acquisitions were recorded with a reso-
lution setting of 70,000, an AGC target of 3 × 106 and a 
maximum injection time of 300 ms. The parameters used 
were; a HESI-II ionization probe (Thermo Fisher Scien-
tific Inc.) with a heater temperature of +300 °C; a spray 
voltage of +4.1 kV; a capillary transfer tube temperature 
of +320 °C; a sheath gas flow rate of 25 and an auxiliary 
gas flow rate of 10.
Using the isotope labeled peptides the normalized col-
lision energy (NCE) in the HCD cell was optimized for 
each individual peptide used in the PRM analysis. This was 
accomplished by direct infusion of respective peptide solu-
tion. A short method employing acquisitions of both intact 
peptide ion spectra and fragment ion spectra having differ-
ent NCE settings was utilized. The best NCE setting could 
then be determined by calculating the respective fragment 
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ion-to-precursor ion-area ratio or simply by manually 
inspecting the quality of the fragment spectra.
IP‑HR‑PRM‑MS method variability
Using the described HR-PRM-MS analysis configuration, 
the analysis behavior of the isotope labeled peptides was 
investigated by the injection of three separate mixtures of 
the these peptides diluted in 50 mM NH4HCO3 to a final 
concentration of 3  nM LAMP2 aa 133–144, 145–152, 
and 153–161; 33 nM of LAMP2 aa 334–351; and 7 nM of 
BSA aa 421–433. Of the isotope labeled peptide mixtures 
15 µL were injected in replicates of ten from multiple LC 
vials or ten times from a single vial. The variability of the 
IP-HR-PRM-MS method was evaluated using an approach 
divided in two pathways, Workflow 1 and Workflow 2, 
described schematically in Fig.  2. In short, Workflow 1 
was used for evaluating the overall variability of the total 
IP-HR-PRM-MS method whereas Workflow 2 targeted the 
variability solely in the LC-HR-PRM-MS analysis. Initially, 
LAMP2 was immunoprecipitated from the QC sample 
of which 8 + 8 replicate samples were prepared for each 
workflow on three separate occasions denominated Batch 
1–3. In Workflow 1 each sample was prepared and ana-
lyzed individually. In Workflow 2 the eight replicate sam-
ples prepared on the same occasion were pooled before the 
LC-HR-PRM-MS analysis, thus being equivalent to multi-
ple injections of the same sample. The samples immuno-
precipitated and digested with trypsin on three different 
occasions were analyzed by LC-HR-PRM-MS on a single 
occasion in a randomized integrated succession. For this 
reason the analysis was only to a limited extent compro-
mised by varying instrumental performance.
Quantitative analyses
Using selected fragment ions, see Table 1, produced from 
tryptic and isotope labeled peptide pairs, PinPoint v1.4 
(Thermo Fisher Scientific Inc.) was employed for deter-
mining fragment ion peak areas. This was done using a 
MS accuracy setting of 10 ppm centered at 0, a MS/MS 
accuracy of 10  ppm and the isolation mode set to MS/
MS with an isolation width setting of 9 u. The peaks were 
detected using a chromatographic peak width setting of 
0.5  min and a minimum signal threshold of 1. A possi-
ble retention time alignment error of 2 min was allowed. 
The complete peak area was determined after using four 
points of smoothing. The detected fragment ion peaks 
were manually inspected for accuracy and absence of 
interferences from other compounds than the peptide 
of interest. The exported fragment ion peak areas were 
processed using an in-house developed software, which 
facilitated further inspection of possible interferences. 
Then, for each peptide, the sum of the included fragment 
ion peak areas were calculated followed by calculation of 
the ratio between the sum of fragment ion peak areas of 
the tryptic peptide against the sum of areas of the added 
isotope labeled peptide. The calculated values used in this 
report are presented in Additional file 4: Table S3.
Statistics
Statistical analyses were performed using GraphPad 
Prism v6.04 (GraphPad Software, Inc., La Jolla, CA, 
USA). Shapiro–Wilk test for normality was used in 
combination with distribution statistics to evaluate the 
normality in the distribution, where a test statistics of 
a p value ≥0.05 suggests normality. Non-parametric 
Mann–Whitney U test of ranks was used for compari-
sons between groups where statistical significance was 
determined as p values <0.05 and a 95 % CI not compris-
ing 0. Spearman’s test of correlation was used to evaluate 
the correlation between the measured levels of LAMP2 
peptides and between the peptides and the AD core bio-
markers. The correlation was evaluated using Spearman’s 
ρ and was considered to have a slope significantly differ-
ent from 0 when p < 0.01.
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